Dr. Clay Siegal currently works at Seattle Genetics as the Chief Executive Officer. The firm is a Seattle-based biotech firm that focuses on the development of therapy for diseases, which are yet to receive substantial mortality improvement for decades. His relentless efforts at the University of Maryland earned him a BS in Zoology. He went ahead to pursue a Ph.D. at George Washington University. Since its inception in 1998, Dr. Siegal has led the biotech firm to become one of the leading manufacturers of therapeutic drugs for diseases such as cancer. In fact, he initiated the creation of the world’s first antibody drug that was FDA-approved. Its antibody-drug conjugate has been approved in many countries.
Dr. Clay Siegal also initiated the development of over 20 varieties of drugs for ultra-rare disease treatment. He also initiated the formation of strategic partnerships with renowned pharmaceutical firms such as Pfizer, Genentech, and Bayer. Under the leadership of Dr. Clay Siegal, the biotech firm has grown from a tiny biotech firm with just a few researchers to an internationally recognized player in the cancer research industry. Dr. Clay Siegal has a bright vision for the future of Seattle Genetics. The biotech firm stands a chance to usher the 21st century with authority in cancer research world. It has an ever-expanding list of drugs that it intends to manufacturer down the road. Its existing portfolio of drugs has an ever-increasing demand.
Dr. Clay Siegal believes that the traditional cancer therapy drugs including systematic chemotherapy are destined for elimination. As technology continues to evolve and the value and efficacy of targeted cancer treatment continues to become clearer, Dr. Sieagl believes that the more efficient targeted drugs will supplant the older cancer therapies. Dr. Siegal has always been drawn to the world of medicine, desire to overcome diseases, and the power of technology. He first became interested in cancer research space while pursuing a degree in Zoology at the University of Maryland. He was inspired to venture into cancer research space after a family member got diagnosed with cancer. Over time, he started learning about different cancer treatments such as amputation and radical surgery.